Paper Details

  1. Home
  2. Paper Details

New developments in the drug treatment of glaucoma.

Author: CrawfordK, HurvitzL M, KaufmanP L, RobinA L, ShawB, WeinrebR N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Glaucoma is a disease that can lead to blindness. It is treated with medications that lower intraocular pressure (IOP). Standard treatment modalities include parasympathomimetic agents, adrenergic agonists, and beta-blockers. Newer drugs under development include apraclonidine, topical carbonic anhydrase inhibitors, and prostaglandins.
Paper Details　
Original Abstract of the Article :
This article reviews standard treatment modalities for patients with glaucoma and describes 3 classes of drugs which are undergoing development: apraclonidine (aplonidine, ALO 2145), an alpha 2-adrenergic agonist which has been released for clinical use; topical carbonic anhydrase inhibitors, a modi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00003495-199141040-00002

データ提供：米国国立医学図書館（NLM）

Glaucoma Treatment: New Developments in Drug Therapy

This research delves into the ever-evolving landscape of [glaucoma treatment], exploring the latest advancements in drug therapy. The study focuses on three classes of drugs undergoing development: [apraclonidine (aplonidine, ALO 2145), topical carbonic anhydrase inhibitors, and prostaglandins (PGs)]. The authors provide an overview of the mechanisms of action and potential benefits of these new drugs, offering promising solutions for managing this chronic eye condition.

Glaucoma Management: Finding New Ways to Lower Intraocular Pressure

The study highlights the importance of finding new and effective ways to manage [intraocular pressure (IOP)] in patients with glaucoma. The authors discuss the potential of [apraclonidine, topical carbonic anhydrase inhibitors, and prostaglandins] to lower IOP and prevent further vision loss. This research encourages further investigation into the efficacy and safety of these new drugs, offering hope for improved glaucoma treatment.

Protecting Our Eyesight: Understanding and Managing Glaucoma

This research underscores the importance of understanding [glaucoma] and seeking early diagnosis and treatment. The authors emphasize the potential of new drug therapies like [apraclonidine, topical carbonic anhydrase inhibitors, and prostaglandins] to manage this condition effectively. This research encourages individuals to consult with their ophthalmologist regularly for comprehensive eye exams and discuss treatment options to protect their eyesight.

Dr. Camel's Conclusion

Just as a camel's keen eyesight allows it to navigate the vast desert, our eyes are a precious gift. This research, like a clear desert sky, offers a glimpse into the future of glaucoma treatment. The development of new drugs like [apraclonidine, topical carbonic anhydrase inhibitors, and prostaglandins] offers a beacon of hope for managing this condition and preserving our precious eyesight. Remember, regular eye exams are crucial to detect and manage glaucoma early, ensuring a brighter future for our vision.

Date :
  1. Date Completed 1991-08-08
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

1711957

DOI: Digital Object Identifier

10.2165/00003495-199141040-00002

Related Literature

Article Analysis
・Side Effects of betaxolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.